Lipocine Inc. (NASDAQ: LPCN)
$4.6500
+0.0600 ( +3.80% ) 3.2K
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
Market Data
Open
$4.6500
Previous close
$4.5900
Volume
3.2K
Market cap
$24.60M
Day range
$4.6350 - $5.0470
52 week range
$3.2000 - $11.7900
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 61 | Jan 13, 2025 |
4 | Insider transactions | 1 | Jan 02, 2025 |
4/a | Other | 1 | Jan 02, 2025 |
8-k | 8K-related | 15 | Dec 17, 2024 |
8-k | 8K-related | 60 | Dec 13, 2024 |
8-k | 8K-related | 15 | Nov 18, 2024 |
8-k | 8K-related | 14 | Nov 07, 2024 |
10-q | Quarterly Reports | 69 | Nov 07, 2024 |
8-k | 8K-related | 16 | Nov 05, 2024 |
8-k | 8K-related | 16 | Oct 31, 2024 |